300 Final analysis of a prospective, randomized, double-blind, placebo-controlled phase IIb trial of tumor lysate, particle-loaded, dendritic cell vaccine in stage III/IV melanoma: 36-month analysis

• Thomas Wagner,
• Timothy Vreeland,
• Guy Clifton,
• George Peoples,
• Diane Hale,
• Mark Faries,
• Montaser Shaheen,
• Lexy Adams,
• Robert Chick,
• Patrick McCarthy,
• Anne O’Shea,
• Phil Kemp Bohan,
• Annelies Hickeron,
• John Myers,
• Jessica Cindass,
• John Hyngstrom,
• Adam Berger,
• James Jakub,
• Jeffrey Sussman

Affiliations

Thomas Wagner

8Orbis Health Solutions, Greenville, SC, USA

Timothy Vreeland

1Brooke Army Medical Center, San Antonio, TX, USA

Guy Clifton

1Brooke Army Medical Center, San Antonio, TX, USA

George Peoples

9Cancer Vaccine Development Program, San Antonio, TX, USA

Diane Hale

1Brooke Army Medical Center, San Antonio, TX, USA

Mark Faries

2John Wayne Cancer Institute, Los Angeles, CA, USA

Montaser Shaheen

7University of Arizona, Pheonix, AZ, USA

Lexy Adams

1Brooke Army Medical Center, San Antonio, TX, USA

Robert Chick

1Brooke Army Medical Center, San Antonio, TX, USA

Patrick McCarthy

1Brooke Army Medical Center, San Antonio, TX, USA

Anne O’Shea

1Brooke Army Medical Center, San Antonio, TX, USA

Phil Kemp Bohan

1Brooke Army Medical Center, San Antonio, TX, USA

Annelies Hickeron

1Brooke Army Medical Center, San Antonio, TX, USA

John Myers

1Brooke Army Medical Center, San Antonio, TX, USA

Jessica Cindass

1Brooke Army Medical Center, San Antonio, TX, USA

John Hyngstrom

3University of Utah, Salt Lake City, UT, USA

Adam Berger

4Rutgers Cancer Institute of New Jersey, philadelphia, PA, USA

James Jakub

5Mayo Clinic, Rochester, MN, USA

Jeffrey Sussman

6University of Cincinatti, Cincinnati, OH, USA